Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...

HIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...

Both lenacapvir and Truvada were generally well-tolerated and Gilead said there were no significant or new safety concerns ..

Twice-a-year-PReP will only fulfill its potential if Medicaid takes decisive action to ensure it is accessible to the ...

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company wi ...

In the 80′s, contracting HIV was considered a death sentence. In the 90′s, HIV was the number one cause of death among ...

Young people living with HIV play a critical role in the fight against AIDS in communities. They offer support and share ...

Chen told The Advocate ahead of HIV/AIDS and Aging Awareness Day that he and others living with HIV have to be aware of both ...

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has raised alarm over the increasing incidence of HIV among young ...

It is not making major news headlines like in the ‘80s, but HIV remains a significant health concern. In 2021, 1.9 million ...